Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.38 |
| ▸ | CDC42BPB | Q9Y5S2 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 8/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573962 | 1.00 | USP30 (0.38) | USP30ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL23573963 | 1.00 | USP30 (0.38) | USP30ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL23574056 | 1.00 | USP30 (0.38) | USP30ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL23574045 | 1.00 | USP30 (0.38) | USP30ROCK2ROCK1CDC42BPBATM | |
| SCHEMBL30801843 | 0.83 | SLC6A2 (0.37) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL30801832 | 0.83 | SLC6A2 (0.37) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL30801867 | 0.83 | SLC6A2 (0.37) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL30801794 | 0.83 | SLC6A2 (0.37) | ROCK2ROCK1CDC42BPBATMPIK3C3 | |
| SCHEMBL23574086 | 0.75 | USP30 (0.61) | USP30 | |
| SCHEMBL23574113 | 0.75 | USP30 (0.61) | USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | claimed |
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | claimed |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| CN-112513036-B | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | 福马治疗有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3793997-B1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS INC (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| CN-112513036-A | Fused bicyclic compounds as ubiquitin-specific peptidase 30 inhibitors | 福马治疗有限公司 | 2021-03-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198263-A1 | FUSED BICYCLIC COMPOUNDS USEFUL AS UBIQUITIN-SPECIFIC PEPTIDASE 30 INHIBITORS | USP30, UCHL1, ADRM1 | USP30 1/4885ROCK2 4284/4885ROCK1 4146/4885 |
| US-12049466-B2 | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors | USP30, UCHL1, ADRM1 | USP30 1/4885ROCK2 4284/4885ROCK1 4146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.